Keywords: Incyte, Jakafi, Ruxolitinib, Novartis, Myelofibrosis, Pfizer, Prevnar 13, USA, FDA

FDA approves Incytes’ Jakafi, first drug to treat MF; advisory panel backs Pfizer’s Prevnar 13 for adults

Article | 17 November 2011

Print This

USA-based Incyte (Nasdaq: INCY) saw its shares rise 10% to$13.90 on the news that the Food and Drug Administration had approved ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in